ACE Extended Cancer Panel for DNA

The ACE Extended Cancer Panel covers a core set of >1,400 cancer-related genes, including clinically-actionable* genes as well as genes that have been identified in the literature as having a role to play in tumorigenesis. The panel provides deep and uniform coverage of genes associated with functional pathways that are known to be involved in cancer biology and it can be used to identify SNVs, indels, and CNAs in these genes. The panel’s accuracy has been enhanced with the utilization of our proprietary ACE Technology, which augments and repairs coverage gaps, especially in problematic regions such as those with high-GC content. This results in the characterization of genes with more complete coverage and greater variant detection performance than that of standard targeted NGS panels.

*Genes referred to here as being clinically-actionable reflects the fact that the efficacy of cancer drugs, FDA-approved or in clinical trials, are thought to be modulated by variants in these genes. This does not imply that this panel is for clinical use – it is for Research Use Only.

Technical Details
Genes covered>1,400
Sequencing informationConfiguration: >500X (tumor)/>100X (normal)
Read length: 2x150bp
Instrumentation: Illumina NovaSeq
Assay sensitivity>99%
Assay specificity (PPA)>99%
Cancer analysis configurationPaired tumor/normal or tumor only
SpeciesHuman

 

ACE Extended Cancer Panel for RNA

The ACE Extended Cancer Panel for RNA provides highly-accurate detection performance for variant types that are more difficult to identify with DNA sequencing analysis alone. The panel enables the identification of gene fusions, SNVs, and indels in the same >1,400 cancer-associated genes as the ACE Extended Cancer Panel for DNA, while also providing gene expression information for each of these genes. This assay enables the discovery of both clinically-actionable fusions involving critical genes such as ALK, ROS1, and RET, as well as novel fusions involving other targeted genes that might be missed by NGS panels that either target a smaller number of genes or that don’t provide RNA information.

As has been discussed in previous sections, Personalis’ targeted approach to RNA sequencing provides researchers with higher quality RNA results compared to those achieved by conventional practices. We accomplish this by focusing only on genes related to cancer biology (by excluding intronic RNA from unspliced transcripts) and by using a capture method that can isolate degraded RNA (which is particularly common in tumor FFPE samples) better than alternative methods. This results in higher quality RNA reads with minimized background.

Technical Details
Genes covered>1,400
Sequencing informationConfiguration: 5M paired-end (10M total)
reads; 2x150bp
Instrumentation: Illumina NovaSeq
Cancer analysis configurationTumor only
SpeciesHuman